Genentech Returns Melanoma Asset to Hanmi; Korean Trials Next
Genentech has returned a licensed melanoma drug to Hanmi Pharmaceutical, which now plans Korean clinical trials while seeking a new partner to advance the asset.
Topic
Drug Partnering
Topic